RECURSION PHARMACEUTICALS, INC. — Form 8-K

Recursion reported Q2 2026 results with three key developments: (1) Genentech exercised its first Validated Target Option under the Roche/Genentech neuroscience collaboration, advancing a previously unexplored neuroscience target into early discovery—a milestone worth $3M and demonstrating platform validation; (2) REC-4881 (MEK1/2 inhibitor for FAP) showed 43–53% median polyp burden reduction with durable effect post-treatment, with additional Phase 2 data to be presented at CGA-IGC in November 2026 and FDA regulatory update expected in 2H26; (3) REC-7735 (PI3K-alpha H1047R inhibitor) received IND clearance with Phase 1/2 ZINNIA trial initiation planned 2H26. Separately, cash position stood at $556.8M (June 30, 2026) vs. $753.9M (Dec 31, 2025); 2026 cash operating expense guidance reduced to <$375M (from <$390M); Q2 net loss was $131.0M on $7.7M revenue.